Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.64 |
| ▸ | PRKCA | P17252 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1866116 | 1.00 | ALDH1A1 (0.70) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL1866113 | 1.00 | ALDH1A1 (0.70) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL20515564 | 0.98 | ALDH1A1 (0.68) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Benzoic Acid SCHEMBL136510 | 0.95 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Benzoic Acid SCHEMBL7688676 | 0.95 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Benzoic Acid SCHEMBL28388934 | 0.95 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Benzoic Acid SCHEMBL9956241 | 0.95 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Acetic Acid SCHEMBL28698833 | 0.95 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL7144537 | 0.91 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL295042 | 0.90 | ALDH1A1 (0.78) | ALDH1A1ADRB2ADRB1ADRB3PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1649 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374609-A1 | NITROSAMINE IMPURITY, VARENICLINE PHARMACEUTICAL COMPOSITION CAPABLE OF REDUCING GENERATION OF NITROSAMINE IMPURITIES AND PREPARATION AND USE THEREOF | VIWIT PHARMACEUTICALCO LTD (CN) | 2024-11-14 | — | — | US | claimed |
| EP-4389748-A2 | NITROSAMINE IMPURITY, VARENICLINE PHARMACEUTICAL COMPOSITION CAPABLE OF REDUCING GENERATION OF NITROSAMINE IMPURITIES AND PREPARATION AND USE THEREOF | Viwit Pharmaceutical Co., Ltd. (CN) | 2024-06-26 | — | — | EP | claimed |
| US-12016917-B2 | Peanut formulations and uses thereof | Société des Produits Nestlé S.A. (CH) | 2024-06-25 | — | — | US | claimed |
| CN-117715910-A | Nitrosamine impurity, valicarb pharmaceutical composition capable of reducing nitrosamine impurity generation, and preparation and application thereof | 威智医药股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-117442575-A | Vanilla pharmaceutical composition and preparation and application thereof | 山东威智中科药业有限公司 | 2024-01-26 | — | — | CN | claimed |
| US-20230139230-A1 | EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF | AIMMUNE THERAPEUTICS, INC. | 2023-05-04 | — | — | US | claimed |
| CN-115721724-A | Pharmaceutical composition containing secondary amine compound and preparation and application thereof | 山东威智中科药业有限公司 | 2023-03-03 | — | — | CN | claimed |
| CN-115721625-A | Pharmaceutical composition containing mirabegron and preparation and application thereof | 山东威智中科药业有限公司 | 2023-03-03 | — | — | CN | claimed |
| CN-115707470-A | Vanillan pharmaceutical composition with low nitrosamine impurity content, and preparation method and application thereof | 山东威智中科药业有限公司 | 2023-02-21 | — | — | CN | claimed |
| CN-115707703-A | Nitrosamine compound, preparation method thereof, application of nitrosamine compound in detection of valnemulin tartrate bulk drug or preparation and detection method | 山东威智中科药业有限公司 | 2023-02-21 | — | — | CN | claimed |
| US-8030338-B2 | Method for producing 2-nitroimidazole derivative | POLA PHARMA INC. (JP) | 2011-10-04 | — | — | US | claimed |
| US-20110201731-A1 | METHOD FOR PREPARING A THERMOPLASTIC COMPOSITE MATERIAL CONTAINING NANOTUBES PARTICULARLY CARBON NANOTUBES | ARKEMA FRANCE (FR) | 2011-08-18 | — | — | US | claimed |
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2010-01-07 | — | — | US | claimed |
| EP-2128140-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | Pola Pharma Inc. (JP) | 2009-12-02 | — | — | EP | claimed |
| US-20090257968-A1 | Gels containing anionic surfactants and coupling agents | WALTON RICHARD | 2009-10-15 | — | — | US | claimed |
| US-20050220832-A1 | Gels containing metallic soaps and coupling agents | WALTON RICHARD | 2005-10-06 | — | — | US | claimed |
| US-5807540-A | Nail varnish composition comprising a crosslinked polyester | L'OREAL (FR) | 1998-09-15 | — | — | US | claimed |
| EP-0740933-B1 | Nail varnish composition containing a crosslinked polyester | OREAL (FR) | 1997-03-26 | — | — | EP | claimed |
| US-5336692-A | High-molecular-weight petrolatum, solvent and a compound both hydrophobic and hydrophilic; protective coatings for skin; moisturizers; spreadability; long-lasting | MEDICIS PHARMACEUTICAL CORPORATION (US) | 1994-08-09 | — | — | US | claimed |
| WO-1992000077-A1 | IMPROVED OINTMENT BASE AND METHOD OF USE | MEDICIS CORPORATION (US) | 1992-01-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374609-A1 | NITROSAMINE IMPURITY, VARENICLINE PHARMACEUTICAL COMPOSITION CAPABLE OF REDUCING GENERATION OF NITROSAMINE IMPURITIES AND PREPARATION AND USE THEREOF | UGT2B7, CYP3A7, CYP2C9 | ALDH1A1 318/4885ADRB2 109/4885ADRB1 119/4885 |
| US-20050220832-A1 | Gels containing metallic soaps and coupling agents | MSN, S100P, STMN1 | ALDH1A1 3458/4885ADRB2 4713/4885ADRB1 4794/4885 |
| US-20230139230-A1 | EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF | ALB, SON, MAX | ALDH1A1 4776/4885ADRB2 4488/4885ADRB1 4571/4885 |
| US-20090257968-A1 | Gels containing anionic surfactants and coupling agents | RAB5IF, ANXA4, ANXA11 | ALDH1A1 4621/4885ADRB2 1825/4885ADRB1 2053/4885 |
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | GALK1, HOGA1, DERA | ALDH1A1 519/4885ADRB2 2232/4885ADRB1 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.